Pregabalin Capsule
Product Images NDC 69367-329

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 69367-329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of pregabalin, highlighting its molecular formula with an amino group (NH2) and a carboxylic acid group (CO2H) attached to a branched carbon chain.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg doses taken three times a day, compared to placebo. Higher doses correspond to greater patient improvement percentages, with Pregabalin 200 mg showing the highest improvement.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Two curves compare Pregabalin 100 mg three times a day and placebo, illustrating patient improvement rates across different pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules at 75 mg, 150 mg, and 300 mg doses taken two times a day compared to placebo. The graph illustrates variation in patient response across different dose levels of Pregabalin and placebo.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline among three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo. The graph shows that higher doses of Pregabalin correspond to higher patient improvement percentages in pain reduction compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin 06)

This chart compares the percent of patients reporting improvement relative to their baseline pain levels for three groups: those taking Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. Lines represent each treatment group's response distribution.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart showing responder rates (%) from two clinical studies, Study E1 and Study E3, comparing placebo and various dosages of pregabalin. The x-axis presents treatment groups including placebo and multiple pregabalin dosages in mg/day, with responder rate percentages labeled above each bar. Study E1 displays responder rates ranging from 14% for placebo to 51% for 600 mg/day pregabalin, while Study E3 shows rates from 9% for placebo to 49% for 600 mg/day pregabalin.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting median percent change from baseline in seizure reduction by dose (mg/day) for Pregabalin from multiple studies (E1 BID, E2 TID, E3 BID, E3 TID). Dose values increase along the x-axis with seizure reduction percentage on the y-axis up to 60%. The graph includes statistical significance p-values for observed results.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline with Pregabalin at 600 mg, 450 mg, 300 mg daily doses and placebo. The x-axis shows percent improvement in pain, while the y-axis shows percent of patients improved. Different lines represent the various doses and placebo for comparison.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR (loss to response) over 180 days for Pregabalin versus placebo. The solid line represents Pregabalin, showing a higher percentage of subjects without LTR across days compared to the dashed line representing placebo.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph showing the percent of subjects improved from baseline to week 12 using the BOCF method for Pregabalin versus Placebo. The x-axis represents percent improved from baseline to week 12, and the y-axis shows the percent of subjects improved. Pregabalin is represented by a solid line, showing higher percent improvement over placebo, which is represented by a dashed line.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo groups over Percent improved from Baseline to Week 16 BOCF. The graph has percent of subjects improved on the vertical axis and percent improved on the horizontal axis, showing two descending lines representing the treatment and placebo groups.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Pregabalin Capsules 25 mg oral capsules packaging label by Westminster Pharmaceuticals, LLC. The label includes dosage form and strength, a barcode, and storage instructions. It indicates 90 capsules per container and notes the product is prescription only.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Pregabalin Capsules 50 mg oral dosage form label from Westminster Pharmaceuticals, LLC. The label shows the product name, strength (50 mg), quantity (90 capsules), and storage instructions. It notes the product is prescription only and manufactured by ScieGen Pharmaceuticals, Inc. with packaging details and a barcode.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Label)

Label for Pregabalin Capsules 75 mg, an oral prescription drug by Westminster Pharmaceuticals, LLC. The label shows the strength of 75 mg, contains 90 capsules, and includes a barcode. Storage instructions and a note to dispense the accompanying Medication Guide are also visible.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Pregabalin Capsules 100 mg oral capsules label shows the drug name and strength prominently. The label indicates 90 capsules per package and is marked Rx Only. Manufactured by ScieGen Pharmaceuticals, Inc. and for Westminster Pharmaceuticals, LLC. Dosage and storage instructions are partially visible. Includes a barcode and a logo for Westminster Pharmaceuticals.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Pregabalin Capsules 150 mg box label displaying dosage form as oral capsules with 90 capsules per container. The label includes storage instructions, manufacturer ScieGen Pharmaceuticals, Inc., and labeler Westminster Pharmaceuticals, LLC. The NDC on the label is 69367-328-09.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Pregabalin Capsules 200 mg in an oral capsule form, labeled for prescription use only. The label shows the product name, strength, and includes storage and dispensing instructions. The manufacturer is ScieGen Pharmaceuticals, Inc., with the product labeled for Westminster Pharmaceuticals, LLC. The package contains 90 capsules and features a barcode.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

Pregabalin Capsules 225 mg oral capsule label. The label includes the product name, strength, and indicates dispensing with the accompanying Medication Guide. It also states the manufacturer is ScieGen Pharmaceuticals, Inc., and the labeler is Westminster Pharmaceuticals, LLC. The package contains 90 capsules. Storage instructions and usage notes are included.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Pregabalin Capsules 300 mg oral capsules label by Westminster Pharmaceuticals, LLC. The label includes dosage strength of 300 mg, package size of 90 capsules, and storage instructions at 25°C with permitted excursions. It also contains a barcode and notes to dispense the accompanying Medication Guide to each patient. Manufactured by ScieGen Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.